Full Description
For more than 70 years, McAlpine's Multiple Sclerosis has been the gold standard textbook on the science and clinical practice of MS. The 5th Edition of this classic, landmark text reflects recent advances in this complex field, bringing you up to date with current information on genetics, epidemiology, clinical neurology, pathogenesis, and management of this common neurological disease. Easy to read and abundantly illustrated, this updated reference is a must-have resource for neurologists, neuropathologists, neurophysiologists, researchers, PM&R specialists, and others who can benefit from authoritative, comprehensive coverage of both scientific and clinical aspects of MS.
Discusses recent advances in both diagnosis and management, including improved understanding of MS in childhood and the elderly, anti-MOG disease, treatments of progressive MS, remyelination and neuroprotective therapies, and more
Offers authoritative reviews of the current literature, placed in historical context
Features more than 550 high-quality illustrations clarifying important scientific and clinical concepts
Provides the most authoritative and comprehensive history of the understanding of the disease
Uses a remarkably clear presentation to make complicated data easier to understand
An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date
Contents
1. The story and iconography of MS
2. The course and cost of MS
3. Definition of progressive MS
4. Health economics of MS and its treatment
5. The clinical features and diagnosis of MS
6. The prodrome of MS
7. MS in children and the elderly
8. Assessment of the eye in MS
9. Neuromyelitis opcitca and anti-MOG disease
10. The pathogenesis of MS
11. The treatment of MS
12. Models of care for the patient with MS
13. Monitoring the treatment of MS?
